BIOMAT Database Logo BIOMAT Database Logo

Kappa opioid effects on fetal behavior: central administration of U50,488. 1994

E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Pavlovian Physiological Department, Institute for Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg.

The kappa opioid agonist U50,488 was administered to E21 rat fetuses via intracisternal (IC), intrahemispheric (IH), or intrathecal (IT) injection. The IC administration of U50,488 promoted a threefold increase in motor activity, which was predominated by movements of caudal regions of the body (rearlimbs, body trunk, and tail). The agonist effect was reversed by IC administration of the selective kappa opioid antagonist nor-binaltorphimine. The IH injection of U50,488 had little effect on fetal behavior, but IT injection resulted in pronounced increases in fetal activity, including rearlimb, trunk, and tail movements. The IT administration of nor-binaltorphimine blocked U50,488 effects, whereas IH injection of the antagonist had little influence on fetal behavior. These findings suggest that kappa opioid receptors located in the spinal cord may play a role in the regulation of fetal motor behavior.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005324 Fetal Movement Physical activity of the FETUS in utero. Gross or fine fetal body movement can be monitored by the mother, PALPATION, or ULTRASONOGRAPHY. Fetal Activity,Fetal Activities,Fetal Movements
D005865 Gestational Age The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated from the onset of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. It is also estimated to begin from fertilization, estrus, coitus, or artificial insemination. Embryologic Age,Fetal Maturity, Chronologic,Chronologic Fetal Maturity,Fetal Age,Maturity, Chronologic Fetal,Age, Embryologic,Age, Fetal,Age, Gestational,Ages, Embryologic,Ages, Fetal,Ages, Gestational,Embryologic Ages,Fetal Ages,Gestational Ages
D000700 Analgesics Compounds capable of relieving pain without the loss of CONSCIOUSNESS. Analgesic,Anodynes,Antinociceptive Agents,Analgesic Agents,Analgesic Drugs,Agents, Analgesic,Agents, Antinociceptive,Drugs, Analgesic

Related Publications

E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Effects of the kappa-opioid agonist U50,488 on parturition in rats.
May 1993, British journal of pharmacology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.
November 2004, Psychopharmacology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Antinociceptive effects of the kappa opioid, U50,488: lack of modulation by 5-HT2 antagonists.
January 1993, Psychopharmacology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
U50,488, a highly selective kappa opioid: anticonvulsant profile in rats.
April 1986, The Journal of pharmacology and experimental therapeutics,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons.
January 2005, Experimental neurology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Effects of U50,488, a selective kappa agonist, on atypical mouse opiate systems.
July 1990, Brain research bulletin,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects.
March 2002, Journal of neurophysiology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice.
February 2021, Medicina (Kaunas, Lithuania),
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Aversive properties of the kappa opioid agonist U50,488 in the week-old rat pup.
January 1994, Psychopharmacology,
E S Petrov, and E I Varlinskaya, and S R Robinson, and W P Smotherman, and B R de Costa, and K C Rice
Central administration of cocaine produces age-dependent effects on behavior in the fetal rat.
December 1994, Behavioral neuroscience,
Copied contents to your clipboard!